Atossa Therapeutics' (Z)-endoxifen shows potential in Duchenne Muscular Dystrophy treatment.

Atossa Therapeutics, a biopharmaceutical company, presents growing evidence supporting the potential role of (Z)-endoxifen in Duchenne Muscular Dystrophy (DMD) and Duchenne carrier-associated pathologies (D-CAPs). A newly published peer-reviewed article and an upcoming scientific presentation highlight the rationale for multi-pathway efficacy of (Z)-endoxifen in DMD. The company's investigational therapy may offer new treatment options for this severe, progressive, and fatal neuromuscular disease.